SIGN UP

Robert Davis, Merck CEO

July 28, 2022 10:40 AM EDT

What can Merck afford to buy now? ‘ANYTHING’ it wants

With Keytruda bulling its way past the $5 billion mark for Q2 sales, you could say that the top execs at Merck can be believed …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

view job offer post your job now

TRENDING NOW

GSK kicks off JPM dealmaking with $1B+ buyout of IDRx and its rare cancer drug

J&J looks at potential bid for Intra-Cellular — report

Biogen offers to buy out struggling neuro partner Sage Therapeutics

Post-Hoc: Big Pharma is losing the AI talent war

Chasing the next wave of obesity drugs, Metsera files for an IPO

Updated: CDER Director Patrizia Cavazzoni to step down ahead of Trump presidency